Matches in Wikidata for { <http://www.wikidata.org/entity/Q80142699> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- Q80142699 description "artículu científicu espublizáu n'agostu de 2006" @default.
- Q80142699 description "scientific article published on 01 August 2006" @default.
- Q80142699 description "wetenschappelijk artikel" @default.
- Q80142699 description "наукова стаття, опублікована в серпні 2006" @default.
- Q80142699 name "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
- Q80142699 name "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
- Q80142699 type Item @default.
- Q80142699 label "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
- Q80142699 label "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
- Q80142699 prefLabel "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
- Q80142699 prefLabel "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
- Q80142699 P1433 Q80142699-E48A1F3C-87CE-4393-B322-D92FBBDCD5CB @default.
- Q80142699 P1476 Q80142699-20292EE9-519A-454F-8574-786B54510E4E @default.
- Q80142699 P2093 Q80142699-194235BB-15E3-48B0-A1D0-A2BCB4EF7A4B @default.
- Q80142699 P2093 Q80142699-23F8B5EC-1FC2-43EC-A4FE-0E1042E91992 @default.
- Q80142699 P2093 Q80142699-3834ED07-A5BC-4EDB-AE5E-4FD41BDB328D @default.
- Q80142699 P2093 Q80142699-42397A26-8ED8-4AE9-92CF-95363746BAD3 @default.
- Q80142699 P2093 Q80142699-667CFF8D-B6CE-4813-AB30-E707C1D1AF68 @default.
- Q80142699 P2093 Q80142699-69520A86-0B2A-4430-AF40-FB05C2EAF0D5 @default.
- Q80142699 P2093 Q80142699-6F718C9B-428A-4491-A1EF-57B5E359CEE3 @default.
- Q80142699 P2093 Q80142699-7D9DE3ED-9BCB-4A91-A7B3-2D888840C95B @default.
- Q80142699 P2093 Q80142699-7E3A41ED-F215-4092-B9FB-FA8EF9E78E85 @default.
- Q80142699 P2093 Q80142699-A7222D5D-90BF-4802-B600-C5E405B5358A @default.
- Q80142699 P2093 Q80142699-B3BAB0B2-954A-4384-9460-D0A8E19F2702 @default.
- Q80142699 P2093 Q80142699-B3E024D6-7FB2-4D33-872F-78C90EFABAC8 @default.
- Q80142699 P2093 Q80142699-B666325B-0D77-460F-97BA-0C9EA490B380 @default.
- Q80142699 P2093 Q80142699-C41E7651-5BC5-4631-84CE-E2BA7D3BEEFB @default.
- Q80142699 P2093 Q80142699-CEB5EAF6-3FB9-4257-8432-BF8671805828 @default.
- Q80142699 P2093 Q80142699-D0C82CFE-BEC7-4252-B09E-476BED9DABA6 @default.
- Q80142699 P2093 Q80142699-D2ED6DBE-D012-4B8A-B3E5-B78E725735E8 @default.
- Q80142699 P2093 Q80142699-E0BAEAD8-F8BD-49D9-9280-30D1619662D5 @default.
- Q80142699 P2093 Q80142699-E25CA137-6048-4DF5-97BE-C6548FA67748 @default.
- Q80142699 P304 Q80142699-4C92DC8D-E970-4889-9DD0-316EF44AFF55 @default.
- Q80142699 P31 Q80142699-9808FA0C-6F74-4402-9DD0-3AE1A99DE805 @default.
- Q80142699 P356 Q80142699-33426532-3E16-43B8-A5A3-1A3B53122ED0 @default.
- Q80142699 P433 Q80142699-7E4E1767-70E7-4980-B6ED-5476C37AFD5F @default.
- Q80142699 P478 Q80142699-6901E3ED-8275-44CF-9131-854F4CDCB168 @default.
- Q80142699 P577 Q80142699-55E07EC3-3977-443B-B52F-784A9D1A5F4F @default.
- Q80142699 P698 Q80142699-66564E94-42B0-4058-8E34-735608BC8181 @default.
- Q80142699 P921 Q80142699-26D03E9B-5FFF-4F49-91D4-8D608C6D070E @default.
- Q80142699 P921 Q80142699-326DE46E-D641-493C-9ADC-3ABACE82669D @default.
- Q80142699 P356 JCO.2006.05.8073 @default.
- Q80142699 P698 16921034 @default.
- Q80142699 P1433 Q400292 @default.
- Q80142699 P1476 "Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
- Q80142699 P2093 "Aleksandra Trajkovic" @default.
- Q80142699 P2093 "Alexandra Gerogianni" @default.
- Q80142699 P2093 "Andrea Bezjak" @default.
- Q80142699 P2093 "Arnold Cyjon" @default.
- Q80142699 P2093 "David Fenton" @default.
- Q80142699 P2093 "Dongsheng Tu" @default.
- Q80142699 P2093 "Frances A Shepherd" @default.
- Q80142699 P2093 "Francis Laberge" @default.
- Q80142699 P2093 "Gary Clark" @default.
- Q80142699 P2093 "Joachim von Pawel" @default.
- Q80142699 P2093 "Jonathan Noble" @default.
- Q80142699 P2093 "Joseph Ayoub" @default.
- Q80142699 P2093 "Lesley Seymour" @default.
- Q80142699 P2093 "Martin Reck" @default.
- Q80142699 P2093 "Mauro Zukin" @default.
- Q80142699 P2093 "National Cancer Institute of Canada Clinical Trials Group Study BR.21" @default.
- Q80142699 P2093 "Raymond Tsz-Tong Chan" @default.
- Q80142699 P2093 "Ronaldo de Albuquerque Ribeiro" @default.
- Q80142699 P2093 "Sergio Lago" @default.
- Q80142699 P304 "3831-3837" @default.
- Q80142699 P31 Q13442814 @default.
- Q80142699 P356 "10.1200/JCO.2006.05.8073" @default.
- Q80142699 P433 "24" @default.
- Q80142699 P478 "24" @default.
- Q80142699 P577 "2006-08-01T00:00:00Z" @default.
- Q80142699 P698 "16921034" @default.
- Q80142699 P921 Q16 @default.
- Q80142699 P921 Q47912 @default.